Although approvals were down year-on-year, December saw a rash of drug registrations, which included innovative products like MACI (autologous chondrocytes on an implantable artificial matrix), the antisense molecule Spinraza (nusinersen), and Zinplava, a fully human monoclonal antibody that targets Clostridium difficile toxin B. However, complete response letters predominated more than in previous quarters, with setbacks for Cempra's solithera and Regeneron's sarilumab. Decisions on several biosimilars are on the horizon.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline: 4Q16. Nat Biotechnol 35, 107 (2017). https://doi.org/10.1038/nbt.3797
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3797
